On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

The company’s shares closed yesterday at $29.89. Olson covers the Healthcare sector, focusing on stocks such as Jasper Therapeutics, Viking Therapeutics, and Bicycle Therapeutics. According to ...

In recent trading, Viking Therapeutics Inc (VKTX) stock price has shown some volatility, fluctuating -6.04% over the last five trades and 9.66% over the past 30 trades. This represents a notable shift ...

Viking Therapeutics (NASDAQ: VKTX) soared to center stage earlier this year as a potentially promising player in one of today ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...

While expected and seen as largely incremental, Jefferies analyst Peter Welford in a Tuesday note to investors said the detailed data for three early-stage assets support moving them into Phase IIb ...

Viking Therapeutics reported clinical trial data on Sunday, which excited some investors. Despite signs that Viking's ...